Format

Send to

Choose Destination
Minerva Gastroenterol Dietol. 2013 Mar;59(1):69-87.

Management of non-alcoholic fatty liver disease.

Author information

1
Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disease in the United States. Non-alcoholic steatohepatitis (NASH), the most severe form of NAFLD, has an increased risk for progression to cirrhosis and associated comorbidities such as cardiovascular disease. Metabolic syndrome (MS) including insulin resistance and obesity is central to the development of NASH. Currently there is no definitive treatment for NASH and most of the available treatment options are targeted towards improving various parameters of MS. Treatment of NAFLD includes diet and lifestyle modification, pharmacological interventions and surgical therapies, or a combination of these interventions. This review focuses on the available current and potential future therapies for treating NASH.

PMID:
23478245
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Minerva Medica
Loading ...
Support Center